Ras-MAP kinase signaling pathways and control of cell proliferation: relevance to cancer therapy.
about
Antibody-drug conjugates as novel anti-cancer chemotherapeuticsIdentification and expression analysis of ras gene in silkworm, Bombyx morimRNA expression of DOK1-6 in human breast cancerCharacterization of ERK docking domain inhibitors that induce apoptosis by targeting Rsk-1 and caspase-9.The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphomaHistone modifications induced by MDV infection at early cytolytic and latency phases.Characterization of ATP-independent ERK inhibitors identified through in silico analysis of the active ERK2 structureConnective tissue metabolism and gingival overgrowth.Hereditary gingival fibromatosis: characteristics and novel putative pathogenic mechanisms.Cocoa procyanidins suppress transformation by inhibiting mitogen-activated protein kinase kinaseMicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathyThe resveratrol analogue 3,5,3',4',5'-pentahydroxy-trans-stilbene inhibits cell transformation via MEKSTAT3, a key regulator of cell-to-cell communication in the heart.Equol, a metabolite of the soybean isoflavone daidzein, inhibits neoplastic cell transformation by targeting the MEK/ERK/p90RSK/activator protein-1 pathway.Multiple pathways contribute to the hyperproliferative responses from truncated granulocyte colony-stimulating factor receptors.Phosphorylation of MCT-1 by p44/42 MAPK is required for its stabilization in response to DNA damage.Hdm2 nuclear export, regulated by insulin-like growth factor-I/MAPK/p90Rsk signaling, mediates the transformation of human cells.Cdc2-mediated inhibition of epidermal growth factor activation of the extracellular signal-regulated kinase pathway during mitosis.Hepatocyte transformation and tumor development induced by hepatitis C virus NS3 c-terminal deleted protein.Comparative proteomic investigation of metastatic and non-metastatic osteosarcoma cells of human and canine originUsing Caenorhabditis elegans as a model organism for evaluating extracellular signal-regulated kinase docking domain inhibitorsMolecular imaging of drug-modulated protein-protein interactions in living subjects.The Time Course of JNK and P38 Activation in Cerebellar Granule Neurons Following Glucose Deprivation and BDNF Treatment.University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL.Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer.A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors.Differential gene expression by chrysotile in human bronchial epithelial cells
P2860
Q26800175-81F9DF26-5960-4F29-AF0A-62F4975DE881Q33516862-4B425715-CC20-48D4-9D9B-170412FE6677Q33585060-8C1D8676-1421-4E12-BC97-34B245DCB6F2Q33789572-CE326415-622A-49FD-B300-33E84072AF1EQ35140947-F3C225AD-085E-4F40-9618-E81EE62D2E99Q35503432-07A7B09C-FD12-4104-9D7A-AC7FFE2986BEQ35762145-66A7B9B2-6ED6-403A-84D8-E9219ED9EB5AQ35798724-F8467E22-F644-427D-8BB4-8755EC4D171DQ36692626-61DE4E58-AD87-470A-AE16-006259F92A64Q36777979-BBA6838C-C343-4D9B-905C-5627B18C8E60Q36802746-3DAA56D5-7D33-4ECB-BB6F-FD874BC8021AQ37022473-6A2BA2FA-12B3-46E0-B216-2C85C8D87813Q38187227-FD039744-B5B8-419E-B56A-90860CE25595Q40088825-37B95BED-CF1D-4006-A0A2-9CB0C2B48716Q40215423-42AB8F7B-E3E8-4907-A0DA-F2158D35D39FQ40224674-F1842ABF-E740-4257-AC66-7052E5F39C3EQ40290768-E1A28595-56D5-4807-B141-603EBAFD6E9FQ40423778-9D9F4A5C-333B-4E1A-8CE3-5C47F30D3810Q40664486-DB10B165-E306-4851-9E9C-3D271B625794Q41072795-3FE76B77-6E8F-45F9-B3A0-20E4CC8DB9C8Q41875981-4CC2083C-9DFC-479F-9EC0-FD9CFA24C373Q41877547-AE487033-97C4-4BDF-8D67-4667C84B4732Q42449357-D936B37B-9F9A-4403-9FA9-90F68846AEF1Q46314353-D3E3AF1E-B07F-41DF-AAE1-82F2DA420603Q49586874-F9E7C350-F1A0-4F96-8B97-169041C71476Q53389706-230CABC8-508D-4C67-BA1D-01BBF4890347Q58276222-22B79A4D-7256-4057-92CB-C16CD90C0D80
P2860
Ras-MAP kinase signaling pathways and control of cell proliferation: relevance to cancer therapy.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Ras-MAP kinase signaling pathw ...... : relevance to cancer therapy.
@ast
Ras-MAP kinase signaling pathw ...... : relevance to cancer therapy.
@en
Ras-MAP kinase signaling pathw ...... : relevance to cancer therapy.
@nl
type
label
Ras-MAP kinase signaling pathw ...... : relevance to cancer therapy.
@ast
Ras-MAP kinase signaling pathw ...... : relevance to cancer therapy.
@en
Ras-MAP kinase signaling pathw ...... : relevance to cancer therapy.
@nl
prefLabel
Ras-MAP kinase signaling pathw ...... : relevance to cancer therapy.
@ast
Ras-MAP kinase signaling pathw ...... : relevance to cancer therapy.
@en
Ras-MAP kinase signaling pathw ...... : relevance to cancer therapy.
@nl
P2860
P1476
Ras-MAP kinase signaling pathw ...... : relevance to cancer therapy.
@en
P2093
Paul Shapiro
P2860
P304
P356
10.1080/10408360290795538
P577
2002-09-01T00:00:00Z